Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
03/17/2011
Trade Name:
Alimta
Generic or Proper Name (*):
pemetrexed disodium
Indications Studied:
Refractory and recurrent solid tumors, including osteosarcoma, Ewing sarcoma/peripheral PNET, rhabdomyosarcoma, and neuroblastoma
Therapeutic Category:
Antineoplastic
Ages Studied:
>12 months and d21 years
Study #:
2
Study Type:
Efficacy/Safety
Study Design:
Open Label
No Patients:
72
No Countries:
2
BPCA(B), PREA(P):
B
Asian:
2
Black:
14
White:
48
Unknown:
6
Native Hawaiian or Pacific Islander:
0
American Indian/Alaska Native:
2
Hispanic/Latino:
0
Non-Hispanic/Non Latino:
0
Countries:
US, Canada
-
-